Why Butyrate Supplementation Makes Chronic Gut Dysfunction Worse: The Data They Don't Show You — The Conventional Medicine Debate

Here&#8217;s what mainstream gastroenterology will say: &#8220;Butyrate is beneficial in IBD. Studies show improvements in inflammation. It&#8217;s a safe, natural intervention. The risks are minimal.&#8221; Here&#8217;s what&#8217;s missing from that statement: No measurement of butyrate oxidation capacity in the studied populations No stratification of responders vs. non-responders by butyrate metabolism No tracking of mast cell activation or HDAC inhibition-related side effects No measurement of systemic butyrate exposure over time No long-term cancer outcome data in high-butyrate-accumulating populations This isn&#8217;t the absence of data. It&#8217;s the absence of the right data. And in the absence of mechanistic understanding and proper measurement, recommending butyrate supplementation to patients with dysbiosis is a reversal of the precautionary principle. You&#8217;re recommending a molecule that may accumulate systemically, drive HDAC inhibition pathology, and potentially increase long-term cancer risk&#8212;without measuring whether the patient can even metabolize it. That&#8217;s not standard of care. That&#8217;s negligence.